Expertise in
11
conditions

Karin P. Hartmann

1Department Of Dermatology, Ratzeburger Allee 160, 
Luebeck, SH, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
11
conditions
1Department Of Dermatology, Ratzeburger Allee 160, 
Luebeck, SH, DE 

Overview

Karin Hartmann practices practicing medicine in Luebeck, Germany.

Ms. Hartmann is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Anaphylaxis, and Urticaria Pigmentosa.

She is actively involved in clinical research, co-authoring 199 peer reviewed articles and participating in 4 clinical trials.

Gender

Female

Locations

1Department Of Dermatology, Ratzeburger Allee 160, Luebeck, SH 23538, Germany
Other Locations
Frankfurter Str. 98, Giessen, HE 35392, Germany
Kerpener Str. 62, Koeln, NW 50937, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Enrollment Status: Recruiting
Publish Date: April 06, 2026
Intervention Type: Drug
Study Drug: BLU-263
Study Phase: Phase 2/Phase 3
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
A Three-year, Non-interventional, Prospective, Multicenter Study to Evaluate the Long- Term Effectiveness of Lanadelumab in Real-world Clinical Practice (ENABLE)
A Three-year, Non-interventional, Prospective, Multicenter Study to Evaluate the Long- Term Effectiveness of Lanadelumab in Real-world Clinical Practice (ENABLE)
Enrollment Status: Completed
Publish Date: September 02, 2025
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, Topical Corticosteroid
Study Phase: Phase 3
View 3 Less Clinical Trials

199 Total Publications

Delayed urticaria during treatment with anti-CGRP monoclonal antibodies in migraine.
Delayed urticaria during treatment with anti-CGRP monoclonal antibodies in migraine.
Journal: Headache
Published: December 23, 2025

Frequently Asked Questions about Karin P. Hartmann

Is Karin P. Hartmann a top-rated expert for Systemic Mastocytosis?

MediFind is an objective health platform that identifies experts based on real-world data. Karin P. Hartmann is classified as an Elite expert for Systemic Mastocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Karin P. Hartmann participate in research or clinical trials?

Yes. Karin P. Hartmann has published 199 articles and abstracts on conditions like Systemic Mastocytosis. You can view a list of Karin P. Hartmann's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hartmann's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile